6. Role of Optimal Medical Therapy

Published on 02/03/2015 by admin

Filed under Cardiovascular

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1209 times

History

The patient was a nonsmoker. He had experienced a myocardial infarction in 2003. A coronary angiogram performed in 2003 showed severe left main artery disease and triple vessel disease. He underwent coronary artery bypass grafting (CABG) the same year. Echocardiography was done 6 months after CABG showed left ventricular ejection fraction (LVEF) of 25%. He was diagnosed with New York Heart Association (NYHA) class III disease, and electrocardiography showed sinus rhythm with a left bundle branch block pattern. QRS duration was 150 msec, and no history of ventricular arrhythmia was reported. In view of persistent left ventricular systolic dysfunction and underlying wide QRS duration, cardiac resynchronization therapy with defibrillator (CRT-D) backup was performed. The procedure was uneventful, and the left ventricular lead was inserted in the posterolateral branch of the coronary sinus. He was subsequently followed regularly by the combined heart failure and device clinic.
The patient returned 6 months after CRT-D implantation and was found to be clinically still in NYHA class III. Device interrogation showed that he received 85% biventricular pacing. Other parameters were unremarkable. Follow-up echocardiographic examination showed an LVEF of 25%.

Comments

The patient was both clinically and echocardiographically a CRT nonresponder. It was necessary to explore the potential cause of lack of CRT response.

Current Medications

The patient’s medications are aspirin 80 mg daily, metoprolol controlled-release 12.5 mg daily, ramipril 1.25 mg daily, furosemide 20 mg daily, and simvastatin 20 mg daily.

Comments

The patient received most of the guideline-recommended medications. However, the dosage was not optimal.

Current Symptoms

The patient experienced persistent heart failure symptoms after CRT-D implantation.

Comments

The cause of the patient’s nonresponse to CRT needs to be identified. It is likely due to suboptimal biventricular pacing and suboptimal medical therapy.

Physical Examination

Laboratory Data

Electrocardiogram

Findings

The electrocardiogram revealed sinus rhythm with inadequate biventricular pacing (Figure 6-1) and adequate biventricular pacing after medical therapy (Figure 6-2).

Comments

It is necessary to confirm this is biventricular capturing.

Chest Radiograph

Findings

The chest radiograph revealed cardiomegaly with no evidence of congestion. All leads were in situ.

Echocardiogram

Findings

The echocardiogram in apical four chamber view revealed dyschronous contraction resulting from lack of biventricular pacing (Figure 6-3).
image

FIGURE 6-1 

image

FIGURE 6-2 

Findings

The apical four chamber view showed improved LVEF and significantly less left ventricular cavity dilation after optimal medical therapy (Figure 6-4).

Focused Clinical Questions and Discussion Points

Question

What are the potential causes of CRT nonresponder in this patient?

Discussion

Two obvious factors contributed to the patient’s illness—inadequate biventricular pacing and suboptimal medical therapy with an inadequate dosage of medication.

Question

What should be done to maximize CRT response?
image

FIGURE 6-3 See expertconsult.com for video.

image
image

FIGURE 6-4 See expertconsult.com for video.

image

Discussion

The dosage of metoprolol (Betaloc), a beta blocker, should be increased for two reasons. First we should try to titrate up the dosage of medication to guideline-recommended dosage and the current prescribed dose was too low. Second, the increase of beta blocker can slow intrinsic heart rate while increasing the percentage of biventricular pacing. Higher percentage of biventricular pacing has been shown to correspond to increased CRT treatment efficacy.

Question

Is any other medical therapy appropriate to be added for this patient?

Discussion

An aldosterone receptor blocker4 and digoxin2 can be added according to current recommendations.

Final Diagnosis

The patient’s final diagnosis is suboptimal medical therapy leading to CRT nonresponse.

Plan of Action

The plan of action in this patient was escalation of medical therapy.

Intervention

The dosages of the beta blocker and ramipril were increased, and digoxin and aldactone were added.

Outcome

Further device interrogation showed that biventricular pacing percentage approached 100%, and the latest echocardiography showed the LVEF to be approximately 40%. Clinically the patient was in NYHA class II.

Findings

This case illustrates the importance of optimal medical therapy in patients with CRT. Current device guidelines suggest it is mandatory to give optimal medical therapy before CRT implantation.1 Also, study has led to the suggestion that patients receiving CRT without optimal medical therapy were associated with less echocardiographic and clinical improvement.3

Selected References

1. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533.

2. Epstein A.E., DiMarco J.P. et al. American College of Cardiology/American Heart Association task force on practice guidelines (Writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices); American association for thoracic surgery; Society of thoracic surgeons. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities. J Am Coll Cardiol. 2008;51:e1–e62.

3. Fung J.W., Chan J.Y., Kum L.C. et al. Suboptimal medical therapy in patients with systolic heart failure is associated with less improvement by cardiac resynchronization therapy. Int J Cardiol. 2007;115:214–219.

4. Pitt B., Remme W., Zannad F. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med. 2003;348:1309–1321.